Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scienture Holdings's Other Operating Expense for the
three
months ended in Mar. 2026 was $0.01 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.05 Mil.
Scienture Holdings's quarterly Other Operating Expense
declined
from Sep. 2025 ($0.01 Mil) to Dec. 2025 ($0.00 Mil) but then
increased
from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.01 Mil).
Scienture Holdings's annual Other Operating Expense
increased
from Dec. 2023 ($0.10 Mil) to Dec. 2024 ($0.42 Mil) but then
declined
from Dec. 2024 ($0.42 Mil) to Dec. 2025 ($0.10 Mil).
Scienture Holdings Other Operating Expense Related Terms
Scienture Holdings Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of $0.05 Mil mean?
Scienture Holdings (SCNX) has a Other Operating Expense of $0.05 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Scienture Holdings and its competitors.
Is Scienture Holdings' Other Operating Expense too high?
Scienture Holdings' current Other Operating Expense is $0.05 Mil. Overall, Scienture Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Other Operating Expense compare to WGRX and HEWA?
Scienture Holdings' Other Operating Expense of $0.05 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Healthcare Providers & Services company?
A good Other Operating Expense depends on the Healthcare Providers & Services industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Scienture Holdings and its competitors. Scienture Holdings's current Other Operating Expense is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Fairly Valued. The stock's GF Value™ is $0.35, compared to a current price of $0.37 — trading 7% above its estimated fair value. The current Other Operating Expense is $0.05 Mil. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Other Operating Expense is $0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued.
The current stock price of $0.37 is trading 7% above its estimated GF Value™ of $0.35.
GuruFocus considers Scienture Holdings to be Fairly Valued.
Key valuation signals for SCNX:
Other Operating Expense: $0.05 Mil
GF Value™: $0.35 vs. price of $0.37 (7% above fair value)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score
Get the complete analysis for SCNX
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
